Special genetically engineered MSCs overexpressing OPG that selectively bind to RANKL, but not to TRAIL were designed by Qiang et al. As expected, the osteoclast activity induced by tumor cells expressing mutant OPG was significantly suppressed, suggesting the potential therapeutic value of this technology [89]. Here, TNFSF11 is linked to neoplasm.